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Abstract
Introduction Delayed gastric emptying and feed intolerance
occur frequently in the critically ill. In these patients, gastric
motor responses to nutrients are disturbed. Peptide YY (PYY)
slows gastric emptying. The aim of this study was to determine
fasting and nutrient-stimulated plasma PYY concentrations and
their relationship to cholecystokinin (CCK) in critically ill
patients.
Methods Studies were performed in 19 unselected
mechanically ventilated critically ill patients (12 males; 48 ± 7
years old) in a randomised, single-blind fashion. Subjects
received a 60-minute duodenal infusion of Ensure® at either 1 or
2 kcal/minute. Blood samples were collected at baseline and at
20, 40, 60, and 180 minutes following commencement of the
nutrient infusion for the measurement of plasma PYY and CCK
concentrations (using radioimmunoassay). Patient data were
compared to 24 healthy subjects (17 males; 43 ± 2 years old).
Results Fasting PYY concentration was higher in patients (P <
0.05), particularly in those with feed intolerance (P < 0.05).
Plasma PYY concentrations were higher in patients during
nutrient infusion (area under the curve [AUC] at 1 kcal/minute:
2,265 ± 718 versus 1,125 ± 138 pmol/l.min, P < 0.05; at 2
kcal/minute: 2,276 ± 303 versus 1,378 ± 210 pmol/l.min, P =
0.01) compared to healthy subjects. The magnitude of PYY
elevation was greater in patients during the 1 kcal/minute
infusion (AUC: 441 ± 153 versus 186 ± 58 pmol/l.min, P <
0.05), but not the 2 kcal/minute infusion. Fasting and nutrient-
stimulated plasma CCK concentrations were higher in patients
(P < 0.05). There was a relationship between plasma PYY and
CCK concentrations during fasting (r = 0.52, P < 0.05) and
nutrient infusion (r = 0.98, P < 0.0001).
Conclusion In critical illness, both fasting and nutrient-
stimulated plasma PYY concentrations are elevated, particularly
in patients with feed intolerance, in conjunction with increased
CCK concentrations.
Introduction
A number of hormones released from the small intestine in
response to nutrients modulate gastric emptying and energy
intake [1-3]. Peptide YY (PYY) is an important humoral media-
tor of the entero-gastric feedback mechanism, which leads to
a slowing of gastric emptying and small intestinal transit [4-6]
and possibly to a suppression of energy intake [1,7,8]. PYY
release from the distal small intestine is stimulated both
directly by luminal nutrients, particularly the digestion products
of fat which activate PYY-secreting cells [7], and indirectly by
neuro-endocrine mechanisms, including the release of chole-
cystokinin (CCK) and insulin-like growth factor-1 [8]. The initial
release of PYY after food intake [2,9] is likely to be mediated
by CCK [9] and its subsequent release is likely to be mediated
through stimulation of PYY-secreting cells by luminal nutrients
[9]. Exogenous administration of PYY slows gastric emptying
[3,10], which is associated with an inhibition of antral motility
[10]. This may contribute to a reduction in energy intake and
APACHE = acute physiology and chronic health evaluation; AUC = area under the curve; BMI = body mass index; CCK = cholecystokinin; CV = 
coefficient of variation; ICU = intensive care unit; NG = naso-gastric; PYY = peptide YY; TMPD = trans-mucosal potential difference.Critical Care    Vol 10 No 6    Nguyen et al.
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body weight [11,12]. Similarly, exogenous CCK administration
slows gastric emptying [2-4,6], increases the sensation of full-
ness, and reduces the sensation of hunger and food intake
[5,6].
Delayed gastric emptying, which is manifested as intolerance
to gastric feeding, is common in critical illness [13,14]. Fur-
thermore, up to 40% of patients suffer from malnutrition during
their illness [13-15]. Disturbances in proximal and distal gas-
tric motor activity have been demonstrated in critically ill
patients, both during fasting and after enteral nutrient stimula-
tion [16-18]. Recent evidence shows that the entero-gastric
feedback response to small intestinal nutrients is elevated in
these patients [17], and this elevation may contribute to the
disturbances in gastric motility and emptying.
Although the mechanisms underlying enhanced entero-gastric
feedback in critical illness are poorly defined, abnormal plasma
levels of gut hormones known to modulate nutrient feedback,
such as CCK, PYY, and ghrelin, have been demonstrated
[19,20]. Our group recently reported that both fasting and
nutrient-stimulated plasma CCK concentrations are elevated
in critical illness [19], particularly in patients with feed intoler-
ance, suggesting a contribution of this hormone to delayed
gastric emptying [19]. Similarly, fasting plasma PYY concen-
trations are elevated in the first week of admission to the inten-
sive care unit (ICU) and normalise after three weeks [20].
However, not all gut hormone levels are elevated in critical ill-
ness. Plasma ghrelin is reduced during fasting, increasing to a
normal level as the patient recovers from the illness [20]. There
are currently no data regarding the PYY response to small
intestinal nutrients or its relationship to CCK in critically ill
patients.
The aim of the current study was to assess (a) plasma PYY
concentrations during small intestinal nutrient infusion and (b)
the relationship between plasma PYY and CCK concentra-
tions in critically ill patients. We hypothesised that plasma PYY
concentrations would be elevated in response to duodenal
nutrient stimulation, particularly in patients with feed intoler-
ance. Furthermore, because the release of PYY is influenced
by CCK, an elevated response would be associated with
enhanced CCK secretion.
Materials and methods
Study subjects
Patients
Studies were performed in 19 critically ill patients (12 males;
48 ± 7 years old; body mass index [BMI] 29.4 ± 2.7 kg/m2)
who were admitted to a level 3, mixed ICU. Data on fasting and
nutrient-stimulated plasma CCK levels in these patients have
been published as part of a larger cohort (n = 31), including a
mixture of critically ill patients with and without prior nutritional
support [19]. The patients included in the current study were
those who had received prior enteral feeding via a naso-gastric
(NG) tube, with sufficient serum to perform the PYY assay.
The first criterion was chosen so that the ability to tolerate NG
feeds could be determined. All patients had received enteral
nutrition (Nutrison Standard: gluten- and lactose-free feed;
100 kcal, 4 g of protein, 12.3 g of carbohydrate, and 3.9 g of
fat per 100 ml; Nutricia Nederland N.V., Zoetermeer, The
Netherlands) as part of standard clinical care for a mean dura-
tion of 3.4 ± 0.9 days. Intolerance of gastric feeding was
defined clinically by a gastric aspirate volume of more than
250 ml that was performed every six hours during continuous
NG feeding at a rate of more than or equal to 40 ml/hour
[21,22]. During both fasting and enteral feeding, all patients
received insulin therapy according to a standardised protocol
designed to maintain blood glucose concentrations between
6 and 8 mmol/l [16,21].
All patients were at least 18 years old, were mechanically ven-
tilated, and were sedated with propofol (Mayne Pharma Pty
Ltd, Melbourne, Victoria, Australia) (10 mg/ml; 1 ml contains
approximately 0.1 g of lipid) 24 hours prior to commencement
of the study. Exclusion criteria included any contra-indication
to passage of an enteral tube; previous gastric, oesophageal,
or intestinal surgery; recent major abdominal surgery; and
administration of opioid analgesia, benzodiazepine sedative, or
prokinetic therapy within 24 hours prior to the study.
Healthy subjects
Data were compared with those from 24 healthy volunteers of
similar age (17 males; 43 ± 2 years old; BMI 25.5 ± 1.0 kg/
m2). No subject had evidence of systemic or gastrointestinal
disease or was taking any medication known to affect gastroin-
testinal motility. Healthy subjects were instructed to refrain
from smoking during the 24 hours prior to the study.
The study protocol was approved by the Human Research
Ethics Committee of the Royal Adelaide Hospital and was
conducted according to the National Health and Medical
Research Committee Guidelines for the conduct of research
on unconscious patients. In patients, written informed consent
was obtained from the next of kin prior to enrolment in the
study. All healthy subjects provided written, informed consent
before entering the study.
Study protocol
Patients were studied after a minimum of eight hours of fast-
ing. A 12-French 114-cm naso-duodenal feeding tube (Flexi-
flo; Abbott Ireland Ltd., Dublin, Ireland) was inserted into the
distal duodenum via an endoscopically placed guide-wire
(THSF-35–260; William A. Cook Australia Pty. Ltd., Brisbane,
Australia). Correct placement of the feeding tube in the duo-
denum was confirmed by (a) measurement of the antro-duode-
nal trans-mucosal potential difference (TMPD) of greater than
-15 mV [17,23] and (b) routine x-ray. Radiologically, this was
identified when the tube crossed the midline to the right at theAvailable online http://ccforum.com/content/10/6/R175
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level of the T12 vertebrae and followed the C-shaped curve of
the duodenum.
In healthy subjects, the study was performed after an overnight
fast of at least eight hours. A silicone rubber catheter (Dent-
sleeve Ply Ltd., Adelaide, Australia) with a central feeding
lumen was used to deliver nutrients into the duodenum. The
catheter was inserted transnasally into the stomach and
allowed to migrate into the duodenum by peristalsis, without
the assistance of either sedation or endoscopy. Passage of
the assembly beyond the pylorus was facilitated by small
weights located at the catheter tip. Correct positioning of the
assembly was determined by continuous measurement of the
antro-duodenal TMPD gradient [23]. Radiological confirma-
tion was not performed.
All studies were performed in the morning. Each subject
received a 60-minute duodenal infusion of Ensure® (Abbott
Laboratories, Abbott Park, IL, USA) (composition: 13% pro-
tein, 64% carbohydrate, 21% fat; energy content: 1 kcal/ml) at
either 1 or 2 kcal/minute in a randomised, single-blind fashion.
Ensure® was diluted with normal saline (0.9%) to 1:4 for the 1
kcal/minute infusion and to 1:2 for the 2 kcal/minute infusion;
the resulting solutions were infused at a rate of 240 ml/hour.
Blood samples for the measurement of plasma PYY and CCK
concentrations were collected at baseline (immediately before
nutrient infusion) and at 20, 40, 60, and 180 minutes after
commencement of the nutrient infusion.
Measurement of plasma PYY and CCK concentrations
Blood samples (8 ml) were collected into ice-chilled EDTA
(ethylenediaminetetraacetic acid)-treated tubes containing
400 kIU of aprotinin (Trasylol; Bayer Australia Ltd, Pymble,
Australia) per millilitre of blood and were centrifuged at 4°C
within 30 minutes of collection. The resulting plasma was
stored at -70°C for subsequent analysis. Plasma PYY concen-
trations were measured by radioimmunoassay using an antise-
rum raised in rabbits against human PYY (1–36) (Sigma-
Aldrich, St. Louis, MO, USA) [24]. This antiserum showed less
than 0.001% cross-reactivity with human pancreatic polypep-
tide and sulfated CCK-8 and 0.0025% cross-reactivity with
human neuropeptide Y. Tracer (Prosearch International Aus-
tralia, Malvern, Australia) was prepared by radiolabeling syn-
thetic human PYY (1–36) (Auspep Pty Ltd, Parkville, Australia)
using the lactoperoxidase method. Monoiodo-tyrosine-PYY
was separated from free iodine-125, diiodo-PYY, and unla-
beled PYY by reverse-phase high-performance liquid chroma-
tography (Phenomenex Jupiter C4 300A 5u column cat. no.
00B-4167-EO 250 _ 4.6 mm; Phenomenex Inc., Torrance,
CA, USA). Standards (1.6 to 50 fmol/tube) or samples (200
μl of plasma) were incubated in assay buffer (0.05 M phos-
phate containing 0.5% bovine serum albumin and 0.02%
azide [pH 7.4]) with 100 μl of antiserum at a final dilution of
1:10,000 for 20 to 24 hours at 4°C, 100 μl of iodinated PYY
(10,000 cpm) was then added, and the incubation continued
for another 20 to 24 hours. Separation of the antibody-bound
tracer from free tracer was achieved by the addition of 200 μl
of dextran-coated charcoal containing gelatin (0.015 g of gel-
atin, 0.09 g of dextran, and 0.15 g of charcoal per 30 ml of
assay buffer), and the antibody-bound tracer was incubated at
4°C for 20 minutes and then centrifuged at 4°C for 25 min-
utes. Radioactivity of the bound fraction was determined by
counting the supernatants in a gamma counter. The intra- and
inter-assay coefficients of variation (CVs) were 12.3% and
16.6%, respectively. The minimum detectable concentration
was 4 pmol/l [24].
Plasma CCK concentrations were also measured by radioim-
munoassay [25]. The antibody (C258; lot 105H4852; Sigma-
Aldrich) used binds to all CCK peptides containing the sul-
fated tyrosine residue in position 7, shows 26% cross-reactiv-
ity with unsulfated CCK-8 and less than 2% cross-reactivity
with human gastrin, and does not bind to structurally unrelated
peptides. The intra- and inter-assay CVs were 9% and 15%,
respectively. The detection limit of the assay was 1 pmol/l in
plasma [25].
As plasma CCK clearance is primarily dependent on renal
function, creatinine clearance in all patients was assessed
using the Cockroft-Gault equation and was considered to be
impaired when creatinine clearance was less than 65 ml/hr
[26].
Statistical analysis
Data are presented as mean ± standard error of mean. Differ-
ences in demographic characteristics and in fasting and inte-
grated (as assessed by area under the curve [AUC] from 0 to
180 minutes) plasma PYY concentrations between critically ill
and healthy subjects were assessed using Student's unpaired
t test. Repeated measures analysis of variance was used to
assess (a) differences in nutrient-stimulated PYY responses
between the two groups and (b) differences in the PYY
response to different nutrient loads within each group. A rela-
tionship between plasma PYY and CCK, body weight,
APACHE (acute physiology and chronic health evaluation) II
score, and length of ICU stay was assessed using Pearson's
correlation. A P  value less than 0.05 was considered
significant.
Results
The study procedures were tolerated well by all subjects and
no complications occurred in either group. Nine patients (48.0
± 6.8 years old) and 11 healthy subjects (43.0 ± 2.0 years old)
were randomly assigned to receive a duodenal nutrient load of
1 kcal/minute; 10 patients (51.3 ± 4.4 years old) and 13
healthy subjects (43.1 ± 2.2 years old) received a nutrient load
of 2 kcal/minute. The demographic characteristics and admis-
sion diagnoses of patients are presented in Table 1. Renal
function was impaired in six patients. Eight patients required
inotropic support with infusion of either noradrenaline (n = 6)Critical Care    Vol 10 No 6    Nguyen et al.
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or adrenaline (n = 2). Ten patients did not tolerate NG feeding
before the study. The duration of feeding was similar between
feed-tolerant and feed-intolerant patients (3.2 ± 0.7 versus 3.9
± 1.0 days, respectively).
Over the 24-hour period prior to the study, each patient
received an intravenous infusion of propofol (2,110 ± 430 mg)
administered with 21.1 ± 4.3 g of lipid as vehicle. There were
no differences in either the amount of propofol or related intra-
venous lipid infused over the 24-hour period between (a)
patients who received 1 kcal/minute and 2 kcal/minute infu-
sion or (b) patients with and without feed intolerance.
Effects of critical illness on fasting PYY concentration
Fasting plasma PYY level was higher in critically ill patients
than in healthy subjects (26.7 ± 4.4 versus 16.3 ± 2.0 pmol/l;
P < 0.05). In patients, fasting PYY concentrations correlated
negatively with body weight (r = -0.52, P = 0.05) and posi-
tively with length of stay in ICU (r = 0.47, P < 0.05). In con-
trast, there was no correlation between fasting PYY
concentration and body weight in healthy subjects. Fasting
PYY level in patients with impaired renal function was similar
to that of individuals with normal renal function (25.4 ± 9.4 ver-
sus 27.3 ± 5.0 pmol/l, P = 0.86). There was no correlation
between fasting PYY levels and age, gender, or APACHE II
Table 1
Demographic details and admission diagnoses of critically ill patients
Patient Age 
(years)
BMI 
(kg/m2)
Days in 
ICU
Admission 
APACHE II
Feed-
tolerant
Renal 
function
Inotrope 
support
IV propofol 
(mg/24 
hours)
IV lipid 
associated 
with propofol 
(g/24 hours)
Nutrient 
load
Admission 
diagnosis
1 36 27 3 26 No Normal No 1,200 12.0 1 kcal/
minute
Head injury
2 69 31 3 23 Yes Normal No 2,400 24.0 1 kcal/
minute
Meningitis
3 2 72 01 01 8N oN o r m a l N o6 , 0 0 0 6 0 . 0 1  k c a l /
minute
Head injury
4 66 33 5 26 No Impaired No 1,200 12.0 1 kcal/
minute
Pancreatitis
5 23 25 5 21 No Normal Nor A 720 7.2 1 kcal/
minute
Multi-trauma
6 5 91 91 33 0Y e s N o r m a l N o r  A 4 , 8 0 0 4 8 . 0 1  k c a l /
minute
Sepsis
7 57 35 7 37 No Impaired A 1,200 12.0 1 kcal/
minute
Sepsis
8 2 32 61 02 5Y e s N o r m a l N o1 , 6 8 0 1 6 . 8 1  k c a l /
minute
Burn injury
9 72 29 6 21 Yes Impaired Nor A 1,200 12.0 1 kcal/
minute
Sepsis
10 53 29 3 27 No Impaired Nor A 4,800 48.0 2 kcal/
minute
Sepsis
11 41 41 9 18 No Normal No 1,200 12.0 2 kcal/
minute
Sepsis
12 74 35 5 27 Yes Impaired A 1,440 14.4 2 kcal/
minute
Cardiac failure
13 27 26 2 26 No Normal Nor A 480 4.8 2 kcal/
minute
Pancreatitis
14 47 27 8 19 Yes Normal No 6,000 60.0 2 kcal/
minute
Multi-trauma
15 66 34 4 28 No Impaired No 1,200 12.0 2 kcal/
minute
Cardiac failure
16 55 29 9 30 Yes Normal No 480 4.8 2 kcal/
minute
SDH
17 36 27 11 29 No Normal No 960 9.6 2 kcal/
minute
Multi-trauma
18 55 21 7 22 Yes Normal No 3,120 31.2 2 kcal/
minute
Multi-trauma
19 59 20 6 29 Yes Normal Nor A 720 7.2 2 kcal/
minute
Sepsis
A, adrenaline; APACHE, acute physiology and chronic health evaluation; BMI, body mass index; ICU, intensive care unit; IV, intravenous; Nor A, 
noradrenaline; SDH, subdural haemorrhage.Available online http://ccforum.com/content/10/6/R175
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score. There was a trend for a higher fasting plasma PYY con-
centration in patients who received inotropes compared with
those who had not received inotropic support (31.2 ± 5.8 ver-
sus 23.5 ± 6.0 pmol/l; P = 0.125).
Effects of critical illness on nutrient-stimulated PYY 
concentrations
In both groups, the absolute plasma PYY concentration
increased after 20 minutes of duodenal nutrient infusion and
returned to baseline level by 180 minutes. In healthy subjects,
the increase in plasma PYY concentration plateaued after 20
minutes (Figure 1a). The magnitude of increase in plasma PYY
was greater during the 2 kcal/minute infusion compared with
the 1 kcal/minute infusion (AUC (0–180 min): 412 ± 78 versus
186 ± 58 pmol/l.min; P < 0.05). In contrast, the increase in
plasma PYY concentration in critically ill patients was progres-
sive during the 60-minute nutrient infusion, especially with the
2 kcal/minute infusion (Figure 1a). The magnitude of plasma
PYY elevation in patients was comparable between the 1 and
2 kcal/minute infusions (AUC (0–180 min): 441 ± 153 versus
684 ± 258 pmol/l.min).
Both the absolute and integrated plasma PYY concentrations
during nutrient stimulation were higher in critically ill patients
compared with healthy subjects (Figure 1a; AUC (0–180 min) 1
kcal/minute: 2,265 ± 718 versus 1,125 ± 138 pmol/l.min, P <
0.05; 2 kcal/minute: 2,276 ± 303 versus 1,378 ± 210 pmol/
l.min, P = 0.01). In patients, there was a greater magnitude of
elevation in PYY concentration during the 1 kcal/minute infu-
sion (AUC (0–180 min): 441 ± 153 versus 186 ± 58 pmol/l.min;
versus healthy; P < 0.05), but not the 2 kcal/minute infusion.
In patients, there was a positive correlation between the mag-
nitude of plasma PYY elevation during nutrient infusion and the
Figure 1
Effects of critical illness on plasmaPY          Y       andCCK concentrations Effects of critical illness on plasma PYY and CCK concentrations. Effects of critical illness on plasma (a) PYY and (b) CCK concentrations dur-
ing fasting and duodenal nutrient infusions of 1 kcal/minute (ICU patients, n = 9; healthy subjects, n = 13) and 2 kcal/minute (ICU patients, n = 10; 
healthy subjects, n = 11) compared with healthy age- and gender-matched control group. ICU patients: closed diamond, solid line; healthy subjects: 
open circle, solid line. Fasting and nutrient-stimulated PYY and CCK concentrations were higher in patients compared with the healthy control 
group. *P < 0.05, **P < 0.001 versus healthy subjects. CCK, cholecystokinin; ICU, intensive care unit; PYY, peptide YY.Critical Care    Vol 10 No 6    Nguyen et al.
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Figure 2
Plasma (a) PYY and (b) CCK concentrations during fasting and duodenal nutrient stimulation in feed-tolerant (n = 9) and feed-intolerant (n = 10)  critically ill patients Plasma (a) PYY and (b) CCK concentrations during fasting and duodenal nutrient stimulation in feed-tolerant (n = 9) and feed-intolerant (n = 10) 
critically ill patients. Feed-tolerant patients: open diamond, solid line; feed-intolerant patients: closed square, solid line. Both fasting and nutrient-
stimulated PYY and CCK concentrations were higher in patients with feed intolerance compared with feed-tolerant patients. *P < 0.05, **P < 0.001 
versus feed-tolerant patients. CCK, cholecystokinin; PYY, peptide YY.
Figure 3
Relationship between plasma PYY and CCK concentrations duringfasting andduoden al nutrient stimulation. Relationship between plasma PYY and CCK concentrations during fasting and duodenal nutrient stimulation. Relationship between plasma 
PYY and CCK concentrations during (a) fasting and (b) duodenal nutrient stimulation (expressed as integrated plasma level [area under the curve 
from 0 to 180 minutes] in critical illness [n = 19]). There was a strong positive correlation between integrated PYY and CCK concentrations during 
both fasting (r = 0.52, P < 0.05) and nutrient stimulation (r = 0.98, P < 0.0001) in critically ill patients. CCK, cholecystokinin; PYY, peptide YY.Available online http://ccforum.com/content/10/6/R175
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fasting concentration (r = 0.76, P < 0.0001), body weight (r =
0.45, P < 0.05), and length of ICU stay (r = 0.6, P < 0.05).
There was no relationship between changes in plasma PYY
during nutrient stimulation and APACHE II score.
Effect of critical illness on fasting and nutrient-
stimulated CCK concentrations
In both groups, there was an increase in the absolute plasma
CCK concentration after 20 minutes of duodenal nutrient infu-
sion. Both fasting and nutrient-stimulated CCK concentrations
were higher in patients than in healthy subjects (fasting: 7.3 ±
1.3 versus 4.7 ± 0.5 pmol/l; P < 0.05; and nutrient-stimulated:
AUC (0–180 min) 1 kcal/minute: 608 ± 115 versus 395 ± 30
pmol/l.min; P < 0.05; 2 kcal/minute: 789 ± 98 versus 518 ±
89 pmol/l.min; P  = 0.05; Figure 1b). In both groups, the
plasma CCK concentration had returned to baseline level by
180 minutes. The magnitude of elevation in CCK concentra-
tion was greater in patients during the 2 kcal/minute infusion
(AUC (0–180 min): 255 ± 34 versus 176 ± 22 pmol/l.min, P =
0.045), but not the 1 kcal/minute infusion (AUC (0–180 min): 110
± 42 versus 140 ± 26 pmol/l.min, P = 0. 42), compared with
healthy subjects.
Feed tolerance and gastro-intestinal hormone response 
in critical illness
In feed-intolerant patients, both fasting and nutrient-stimulated
plasma PYY and CCK concentrations were higher than in the
remainder of the group (Figure 2). In feed-intolerant patients,
there was a trend for a greater magnitude of elevation in both
PYY (AUC (0–180 min): 2,743 ± 589 versus 1,526 ± 335 pmol/
l.min; P = 0.09) and CCK (AUC (0–180 min): 258 ± 43 versus
148 ± 35 pmol/l.min; P = 0.07) concentrations compared with
feed-tolerant patients. Both fasting and nutrient-stimulated
PYY and CCK levels were similar between feed-tolerant
patients and healthy subjects.
Relationship between plasma PYY and CCK 
concentrations in critical illness
In patients, there was a strong positive correlation between
integrated plasma PYY and CCK concentrations during both
fasting (r = 0.52, P < 0.05) and nutrient stimulation (r = 0.98,
P < 0.0001; Figure 3). In healthy subjects, there was a positive
correlation between plasma PYY and CCK concentrations
during nutrient stimulation (r = 0.43, P < 0.05), but not during
fasting (r = 0.29, P = 0.27).
Discussion
This study is the first to evaluate the plasma PYY response to
small intestinal nutrients and its relationship to CCK release in
critically ill patients. It was shown that in critical illness, (a)
plasma PYY concentrations are elevated during both fasting
and nutrient stimulation, particularly in patients who are intol-
erant to gastric feeding, (b) the release of PYY in response to
nutrients does not exhibit the same dose dependency as evi-
denced in health, and (c) there is a close relationship between
nutrient-stimulated plasma PYY and CCK concentrations.
These findings are consistent with the concept that the sensi-
tivity of the small intestine to PYY release is increased in criti-
cal illness and suggest a potential contribution of this hormone
to delayed gastric emptying.
The mechanisms underlying the abnormally high plasma PYY
levels during fasting and in response to small intestinal nutri-
ents in critical illness are unclear. In the current study, nutrients
were delivered directly into the duodenum to enable a reliable
assessment of the entero-gastric feedback response because
gastric emptying is frequently disturbed in the critically ill. The
use of 1 and 2 kcal/minute nutrient infusions allowed the eval-
uation of the potential load dependency of the response. The
increase in plasma PYY within 20 minutes of nutrient stimula-
tion is most likely mediated by factors in the proximal small
intestine rather than by direct nutrient stimulation of the distal
ileum. Because prolonged small intestinal transit is common in
critically ill patients [27,28], it is unlikely that nutrients would
have reached the distal ileum within 60 minutes for direct stim-
ulation of PYY release. This notion is further supported by the
subsequent return of plasma PYY to fasting level by 180 min-
utes, suggesting that the clearance of nutrient from the proxi-
mal gut leads to the normalisation of PYY levels.
There are several neuro-hormonal factors related to the proxi-
mal small intestine which can potentially elevate PYY concen-
trations in critical illness. CCK appears to be an important
'proximal' mediator in that (a) it stimulates the release of PYY
[8], (b) fasting and nutrient-stimulated plasma CCK are ele-
vated in the critically ill [19], and (c) both fasting and nutrient-
stimulated plasma PYY concentrations correlate strongly with
CCK. The CCK responses in the current study are consistent
with our previous findings [19]. Although the mechanisms
underlying the CCK elevation in critical illness remain unclear,
recent data suggest that the presence of inflammation, which
can influence the entero-endocrine cells in the small intestine,
may be important [29]. In a mouse model, McDermott and col-
leagues [29] demonstrated that upper gut inflammation, via
specific control of CD4+ T lymphocytes and related inflamma-
tory cytokines (interleukin-3 and interleukin-4), can upregulate
CCK-expressing cells, increase plasma CCK concentrations,
and reduce energy intake. Systemic inflammation with ele-
vated inflammatory cytokines is common in critically ill patients
[27,28] and may be important in mediating the elevated CCK
(and thereby PYY) response to intestinal nutrients. It is also
possible that direct neural stimulation in the proximal intestine
triggers the release of PYY from the distal ileum [30-32]. In
animals, PYY release in response to intestinal nutrients cannot
be abolished by preventing nutrient delivery to the site of PYY-
containing cells in the distal ileum, but only by removing these
cells completely (that is, ileo-colectomy) [31]. These observa-
tions suggest the presence of a neural linkage between the
proximal gut and the distal PYY-secreting cells, involving sen-
sory vagal fibres with nicotinic, beta-adrenergic, opioid, andCritical Care    Vol 10 No 6    Nguyen et al.
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serotonergic synapses and nitric oxide release [30-33]. It
remains to be evaluated whether disturbances of the neuro-
transmitters, such as nitric oxide [28], alter the neural function
of these pathways and increase small intestinal 'sensitivity' to
nutrients in critically ill patients.
Common factors of critical illness such as mechanical ventila-
tion, sedatives, and inotropic therapy may also contribute to
the abnormal PYY and CCK responses to nutrients. Apart
from inducing splanchnic hypoperfusion, mechanical
ventilation with high end-inspiratory pressure can also
increase pulmonary and systemic cytokines [28,34,35], which
may influence the function of the entero-endocrine cells in the
small intestine, as discussed [29]. All patients in the current
study were sedated with propofol. Because this agent is
administered in a lipid emulsion, a possible direct effect on the
hormonal responses cannot be excluded. However, recent
data suggest that a lipid amount equivalent to that adminis-
tered in the current study (20 g) reduced rather than increased
PYY concentrations [36]. Similarly, previous reports indicate
that intravenous lipid has no effect on plasma CCK concentra-
tions [37-39]. There was a trend for higher plasma PYY con-
centrations in patients who received inotropic therapy, but
whether the elevation is a physiological response to shock or
a direct effect of inotropic drugs on PYY release is unknown.
In animals, PYY infusion causes intestinal vasoconstriction
with a simultaneous increase in systemic arterial blood pres-
sure which serves to divert blood from the gastrointestinal
tract to the central vascular system [40]. Further studies are
required to assess these associations, in particular whether
the heightened PYY response to nutrients predisposes
patients to intestinal ischaemia [27].
In the current study, fasting PYY concentrations were 1.5-fold
higher in critical illness than in health, consistent with recent
findings by Nematy and colleagues [20]. In 16 critically ill
patients, these authors found a two-fold increase in fasting
plasma PYY concentrations during acute critical illness, with a
normalisation of PYY levels after three weeks of admission to
the ICU. In these patients, fasting PYY levels were positively
related to changes in appetite and energy intake [20], sug-
gesting a relationship between critical illness, elevated plasma
PYY concentrations, appetite, and possibly gastric emptying.
Our finding of a substantially higher PYY response (approxi-
mately two-fold) to small intestinal nutrients in critical illness,
particularly in patients with feed intolerance, supports such a
relationship and a contribution of PYY to the enhanced entero-
gastric feedback response. The lack of a dose-dependent
response to nutrients in critically ill patients is consistent with
the concept that the 'sensitivity' of the small intestine to PYY
release is enhanced. In non-critically ill patients with cardiac
cachexia associated with primary pulmonary hypertension, an
enhanced 'early' PYY response to an intragastric meal has
been reported [41]. Accordingly, our observations provide a
potential link between abnormal 'entero-gastric' responses
[17] and the frequently observed gastric motor dysfunction
and delayed emptying in the critically ill [16-18,21]. Intoler-
ance to gastric feeding is an indirect marker of delayed gastric
emptying in these patients [21,22]. Together, these observa-
tions support the concept that the humoral mediators of the
'entero-gastric' response are enhanced in critical illness, pro-
viding a potential mechanism for delayed gastric emptying and
subsequent feed intolerance.
The heterogeneity of the critically ill population limits the inter-
pretation of the study data. In particular, various admission
diagnoses that can have an impact on gastric emptying were
included in this study. In light of the normalisation of fasting
PYY levels in critically ill patients after discharge [21], follow-
up studies to examine the long-term recovery of the humoral
response and entero-gastric feedback would be important.
The decrease in plasma ghrelin during critical illness suggests
that the elevated PYY and CCK responses may be a specific
phenomenon. The role and specificity of these hormones in
feed intolerance can be evaluated further by assessing other
gut hormones, such as glucagon-like-peptide 1, secretin, gas-
tric inhibitory polypeptide, neurotensin, and motilin.
Conclusion
Both fasting and duodenal nutrient-stimulated plasma PYY
concentrations are elevated in critical illness, particularly in
patients who are intolerant to gastric feeding. This elevated
response is strongly related to plasma CCK concentrations,
suggesting an important role for this hormone in mediating
increased PYY release. Together, these findings provide an
underlying humoral mechanism for the enhanced entero-gas-
tric reflex and subsequent delayed gastric emptying in critical
illness.
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